首页> 外文OA文献 >Stroke prevention in atrial fibrillation:Past, present and future. Comparing the guidelines and practical decision-making

【2h】

Stroke prevention in atrial fibrillation:Past, present and future. Comparing the guidelines and practical decision-making

机译：心房颤动中的卒中预防：过去，现在和将来。比较指南和实际决策

页面导航

著录项
相似文献
相关主题

著录项

作者
Lip Gregory; Freedman Ben; De Caterina Raffaele; Potpara Tatjana S;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Stroke prevention in atrial fibrillation: Past, present and future Comparing the guidelines and practical decision-making [J] . Lip Gregory Y. H., Freedman Ben, De Caterina Raffaele, Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis . 2017,第7期

机译：心房颤动中的中风预防：过去，现在和未来比较指导和实际决策
2. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
3. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
4. Early Experiences from a Guideline-based Computerized Clinical Decision Support for Stroke Prevention in Atrial Fibrillation [C] . Rong Chen, Carlos Vailadares, Iago Corbal, MEDINFO . 2013

机译：基于指南的计算机化临床决策支持的早期经验支持心房颤动中的中风预防
5. Comparative and Cost-effectiveness of Stroke Prevention Treatments in Atrial Fibrillation: A New Generation of Drugs. [D] . Tawfik, Amy. 2015

机译：心房颤动中风预防治疗的比较和成本效益：新一代药物。
6. Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology [O] . -1

机译：循证指南更新摘要：预防非瓣膜性房颤的中风：美国神经病学会指南制定小组委员会的报告
7. Response to Letter Regarding Article, “Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R 2 CHADS 2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts” [O] . Jonathan P. Piccini, Susanna R. Stevens, YuChiao Chang, 2013

机译：回应关于物品的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R 2 Chads 2指数在火箭AF中（rivaroxaban曾经每日，口服，直接因子XA抑制相比维生素K对患者预防心房颤动的卒中和栓塞试验的拮抗剂）和Atria（心房颤动的抗凝和危险因素）研究队列“

Stroke prevention in atrial fibrillation:Past, present and future. Comparing the guidelines and practical decision-making

著录项

相似文献

相关主题

期刊订阅